- Home
- ACON vs MBIO Comparison
ACON vs MBIO Comparison
Compare ACON & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACON | MBIO |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.7M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACON | MBIO |
|---|---|---|
| Price | $3.42 | $0.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 54.7K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,483.00 | N/A |
| Revenue This Year | $71.77 | N/A |
| Revenue Next Year | $80.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.91 | N/A |
| 52 Week Low | $3.28 | $0.89 |
| 52 Week High | $562.68 | $7.00 |
Technical Indicators
Market Signals| Indicator | ACON | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 37.37 |
| Support Level | $3.68 | $0.96 |
| Resistance Level | $3.75 | $1.10 |
| Average True Range (ATR) | 0.27 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 0.00 | 4.72 |
Price Performance
Historical ComparisonAbout ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.